Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMT004
- Development stage
- Preclinical
- Lead developer
- SirnaMed
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SMT004 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by SirnaMed for the treatment of non-small cell lung cancer (NSCLC). The drug is specifically engineered to target and silence the expression of mutant forms of the epidermal growth factor receptor (EGFR), which are prevalent drivers of oncogenesis and resistance in lung cancer patients. By utilizing the RNA interference (RNAi) pathway, SMT004 facilitates the degradation of mutant EGFR mRNA, leading to a reduction in the corresponding oncoprotein levels and subsequent inhibition of tumor cell proliferation and survival.
- Other names
- SMT004-SirnaMed-mutEGFR-siRNA-NSCLCSMT-004-SirnaMed-mutEGFR-siRNA-NSCLCSMT 004-SirnaMed-mutEGFR-siRNA-NSCLC
02
Targets
Beyond the preview
Go deeper on SMT004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMT004.